Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 6/20 | 0.44 |
| ▸ | UMPS | P11172 | 1/20 | 0.42 |
| ▸ | PYGL | P06737 | 3/20 | 0.39 |
| ▸ | PYGM | P11217 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | STAT6 | P42226 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30287919 | 1.00 | PNP (0.44) | PNPUMPSPYGLPYGMATM | |
| SCHEMBL15803217 | 1.00 | PNP (0.44) | PNPUMPSPYGLPYGMATM | |
| SCHEMBL30295631 | 1.00 | PNP (0.44) | PNPUMPSPYGLPYGMATM | |
| SCHEMBL64635 | 1.00 | PNP (0.44) | PNPUMPSPYGLPYGMATM | |
| SCHEMBL14791302 | 1.00 | PNP (0.44) | PNPUMPSPYGLPYGMATM | |
| SCHEMBL10226283 | 1.00 | PNP (0.44) | PNPUMPSPYGLPYGMATM | |
| SCHEMBL767777 | 1.00 | PNP (0.44) | PNPUMPSPYGLPYGMATM | |
| SCHEMBL17329460 | 1.00 | PNP (0.44) | PNPUMPSPYGLPYGMATM | |
| SCHEMBL21847661 | 1.00 | PNP (0.44) | PNPUMPSPYGLPYGMATM | |
| SCHEMBL30100125 | 1.00 | PNP (0.44) | PNPUMPSPYGLPYGMATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023131254-A1 | PSEUDOURIDINE MODIFIED AT N1 POSITION AND USE THEREOF IN MRNA SYNTHESIS | 上海吉量医药工程有限公司 | 2023-07-13 | — | — | WO | disclosed |
| US-11564998-B2 | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins | MODERNATX, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4015005-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ModernaTX, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3590949-B1 | RIBONUCLEIC ACIDS CONTAINING N1-METHYL-PSEUDOURACILS AND USES THEREOF | MODERNATX INC (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3682905-B1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX INC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-20210308283-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2021-10-07 | — | — | US | disclosed |
| EP-3889602-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | Universität Basel (CH) | 2021-10-06 | — | — | EP | disclosed |
| US-20210077634-A1 | IN VIVO PRODUCTION OF PROTEINS | MODERNATX INC (US) | 2021-03-18 | — | — | US | disclosed |
| US-20200354423-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | MODERNA THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| US-10772975-B2 | Modified Polynucleotides for the production of biologics and proteins associated with human disease | MODERNATX, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110257244-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110130440-A1 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110118339-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110065774-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | ALNYLAM PHARMACEUTICALS (US) | 2011-03-17 | — | — | US | disclosed |
| WO-2010101951-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2009120878-A2 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009099942-A2 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009091972-A2 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091982-A1 | MIR-122 AGONIST | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257244-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF | AGO2, BCDIN3D, TRDMT1 | PNP 1326/4885UMPS 600/4885PYGL 3889/4885 |
| US-20210308283-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | PNP 5/4885UMPS 36/4885PYGL 1513/4885 |
| US-20110065774-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | DCLRE1B, RNGTT, NSUN2 | PNP 732/4885UMPS 651/4885PYGL 2577/4885 |
| US-20210077634-A1 | IN VIVO PRODUCTION OF PROTEINS | NSUN2, RNMT, NSUN3 | PNP 31/4885UMPS 12/4885PYGL 2053/4885 |
| US-11564998-B2 | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins | PHAX, NSUN2, RNMT | PNP 95/4885UMPS 53/4885PYGL 1906/4885 |
| US-20110130440-A1 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | NSUN2, RNMT, RNGTT | PNP 115/4885UMPS 267/4885PYGL 1994/4885 |
| US-20200354423-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | MSH2, POLRMT, SARNP | PNP 128/4885UMPS 220/4885PYGL 3038/4885 |
| US-10772975-B2 | Modified Polynucleotides for the production of biologics and proteins associated with human disease | RNMT, RNGTT, SARNP | PNP 236/4885UMPS 1432/4885PYGL 3946/4885 |
| US-20110118339-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | TRDMT1, NSUN3, BCDIN3D | PNP 915/4885UMPS 439/4885PYGL 4218/4885 |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | PNP 299/4885UMPS 624/4885PYGL 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.